Refers to Sweeney, C. J. et al. N. Engl. J. Med.373, 737–746 (2015) | Fizazi, K. et al. Lancet Oncol.16, 787–794 (2015)
In two recent phase III trials, investigators evaluated the addition of docetaxel to androgen-deprivation therapy for non-castrate prostate cancer. On the basis of the CHAARTED-trial findings, we can firmly conclude that this combination can be used in the metastatic setting. The results of the GETUG 12 trial are less informative, although some benefit for patients with high-risk localized prostate cancer was demonstrated.